Update shared on06 Aug 2025
Fair value Increased 9.38%The notable increase in Medexus Pharmaceuticals' consensus price target is primarily driven by a significant rise in its future P/E valuation, with fair value revised upward from CA$6.50 to CA$7.11.
Valuation Changes
Summary of Valuation Changes for Medexus Pharmaceuticals
- The Consensus Analyst Price Target has risen from CA$6.50 to CA$7.11.
- The Future P/E for Medexus Pharmaceuticals has significantly risen from 10.43x to 15.73x.
- The Discount Rate for Medexus Pharmaceuticals remained effectively unchanged, moving only marginally from 5.95% to 5.97%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.